Abstract
Background
Current clinical trial labels are designed primarily to meet regulatory requirements. These labels have low patient and site utility, few are opened, and they have limited space and small fonts. As our world transitions from paper to electronic, an opportunity exists to provide patients with information about their investigational clinical trial product in a way that is more easily accessible, meets Health Authority requirements, and provides valuable additional information for the patient and caregiver.
Methods
A TransCelerate initiative was launched to understand the current regulatory and technology landscape for the potential use an electronic label (eLabel) for investigational medicinal products (IMPs). Concepts and an example proof of concept were developed intended to show the “art of the possible” for a foundational eLabel and a “universal printed label.” In addition, possible patient-centric enhancements were captured in the eLabel proof of concept. These concepts were shared with Health Authorities as well as patient and site advisory groups to gather feedback and subsequently enhance the concepts.
Results
Feedback indicated that the concept of an eLabel provides value and concepts should continue to be pursued. While the Health Authorities engaged with did not express issues with the use of an eLabel per se, the reduction in the content on the paper label is not possible in some geographic locations due to existing regulations.
Conclusions
There is nothing that prevents transmitting the label electronically in conjunction with current conventional labeling. While there are still some regulatory barriers that need to be addressed for reducing what is on the paper label, advancement toward a more patient-centric approach benefits stakeholders and will enable a fully connected patient-centric experience. The industry must start now to build the foundation
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Sadler-Williams E. Patient perceptions of investigational medicinal products 2015 surveys in EU (and China). Lecture presented at: International Society for Pharmaceutical Engineering (ISPE) European Union (EU) Annual Meeting; March 7-9, 2016; Frankfurt, Germany.
Vanaken H. Digitally enhanced: Janssen drives effort to bring suite of “smart” clinical trials into practice in 2017. http://www.appliedclinicaltrialsonline.com/digitally-enhanced-smart-trial-platform. Accessed November 15, 2017.
Hootsuite and We are Social. Digital in 2017: global overview. https://www.slideshare.net/wearesocialsg/digital-in-2017-global-overview. Accessed November 5, 2017.
The Institution of Engineering and Technology. How “tech savvy” are we? http://www.theiet.org/sectors/thought-leadership/future-cities/articles/tech-savvy.cfm?utm_source=redirect&utm_medium=any&utm_campaign=tech-savvy. Accessed November 5, 2017.
Care Innovations, an Intel GE Company. Older populations have adopted technology for health. http://resources.careinnovations.com/hs-fs/hub/453282/file-2516634380-pdf. Accessed November 5, 2017.
Pew Research Center. Internet and broadband fact sheet (Jan 2017). http://www.pewinternet.org/fact-sheet/internet-broadband/. Accessed November 5, 2017.
AARP. 2016 Technology trends among mid-life and older Americans. https://www.aarp.org/research/topics/technology/info-2016/2016-technology-trends-older-americans.html. Published November 2016. Accessed November 16, 2017.
Gordon ME. Benchmarking the half-life and decay of mobile apps. Flurry Analytics Blog. http://flurrymobile.tumblr.com/post/115191376315/benchmarking-the-half-life-and-decay-of-mobile. Accessed November 5, 2017.
Royal National Institute of Blind People. How many people in the UK have sight loss? RNIB website. https://help.rnib.org.uk/help/newly-diagnosed-registration/registering-sight-loss/statistics. Accessed November 5, 2017.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Smith-Gick, J., Barnes, N., Barone, R. et al. The Near-Term Viability and Benefits of eLabels for Patients, Clinical Sites, and Sponsors. Ther Innov Regul Sci 52, 537–545 (2018). https://doi.org/10.1177/2168479018765463
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1177/2168479018765463